antiviral news

Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure.

Ansun Biopharma, Inc., a clinical-stage biopharmaceutical company, today announced that its independent Data Monitoring Committee (DMC) has issued a positive recommendation following a prespecified interim efficacy and safety review of the Company's Phase 3 clinical trial (DAS181-3-01). DAS181 is being evaluated for the treatment of parainfluenza pneumonia infection in immunocompromised patients requiring oxygen support.

Japan's Shionogi on Monday said it won FDA approval for its oral antiviral to prevent Covid‑19 in adults and children older than 12 years who have been in contact with someone ...

After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. patients, Shionogi has secured an FDA green light for the medicine in the prevention setting.

Japan's Shionogi & Co said on Monday ⁠the U.S. Food and Drug Administration has approved ⁠its oral antiviral Ensitrelvir, commercially known as ⁠Xocova, for the... Reuters Health Information

The FDA approved the oral antiviral agent ensitrelvir (Xocova) to help prevent COVID-19 in people ages 12 years or older who were exposed to the SARS-CoV-2 virus, drugmaker Shionogi announced.